279 results about "Protein level" patented technology

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention discloses an interfering RNA (Ribonucleic Acid) for inhibiting a PCSK9 gene and application of the interfering RNA. The interfering RNA comprises any one or more than two nucleotide sequences as shown in SEQ ID NO: 1-40 and SEQ ID NO: 73-96. The interfering RNA can better target and silence mRNA of the liver PCSK9, reduce the protein level of the PCSK9, enhance LDL-C metabolism and reduce serum cholesterol, and a solid technical basis is provided for research and development of siRNA drugs for prevention and treatment of PCSK9 gene mediated diseases and symptom relief.

The invention provides a double-target degradation molecule based on a functionalized nucleic acid connexon and application thereof, and relates to the technical field of biological medicine, the double-target degradation molecule comprises an E3 ubiquitin ligase ligand at one end, a first target protein ligand at the other end, and the functionalized nucleic acid connexon located between the E3 ubiquitin ligase ligand and the first target protein ligand; the functionalized nucleic acid linker is a nucleotide sequence capable of specifically recognizing and combining a second target protein or a coding gene thereof, so that the protein level degradation of the first target protein and the nucleic acid level or expression level inhibition of the second target protein / gene are realized in the same molecule. Functionalized nucleic acid and a PROTAC strategy are organically combined, single-molecule double-target collaborative intervention is achieved, targeting efficiency and treatment potential are improved, higher flexibility and expandability are provided in synthesis and design, and a new molecular platform and technical route are provided for multi-target accurate treatment.

The invention relates to the technical field of information, and discloses a method for predicting the optimal branched chain amino acid ratio of daily ration of lactating sows, which comprises the following steps of: 1, acquiring production data and feed formula data; 2, processing the production data and the feed formula data to obtain production sample data and formula sample data; 3, performing correlation calculation on the production sample data and the formula sample data to obtain most effective features and calculate feature vectors; 4, training a preset model according to the feature vector and the formula sample data; 5, verifying the preset model, and selecting an optimal prediction model according to an evaluation result; and 6, outputting an isoleucine content prediction value, a leucine content prediction value and a valine content prediction value by the optimal prediction model. The prediction method can accurately and reliably predict the branched chain amino acid proportion of daily ration with different protein levels. Meanwhile, the invention further provides a prediction device for the optimal branched chain amino acid proportion of the daily ration of the lactating sow.

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

The invention discloses a DKA combined AP risk prediction model based on multi-index fusion, a medium and equipment, and relates to the technical field of medical health and artificial intelligence, and the risk prediction model comprises a preprocessing unit which is used for carrying out the standardization processing of basic data and clinical data of a diabetic ketoacidosis patient, the clinical data comprises stomachache symptoms, C reactive protein level and serum lipase level; the screening unit is used for screening the basic data according to an exclusion mechanism; the data integration unit is used for obtaining the probability of occurrence of DKA and AP events by combining the following formula according to the screening result: Q = 1 / (1 + e-(beta0 + beta1 * stomachache + beta2 * CRP + beta3 * LPS)); and the output unit is used for outputting the probability calculated by the data integration unit as a result. Under the emergency treatment scene, the risk of acute pancreatitis complicated by the diabetic ketoacidosis patient can be rapidly evaluated, and a good preposed basis is provided for clinical decision making.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

Aspects of the invention provide an AAV product that delivers an STXBP1 gene supplementation or replacement strategy throughout the human CNS at levels of DNA biodistribution, RNA expression, and hSTXBPlb protein levels expected to restore function in STXBP1 encephalopathy patients.

The invention provides an intelligent optimization method for carbon emission reduction of an ecological pasture in extreme weather, and relates to the technical field of intelligent optimization of carbon emission reduction. Comprising the steps that initial monitoring data are collected and preprocessed, and multi-dimensional feature vector output state features are constructed; an LSTM time sequence prediction model is used for analyzing the state of the dairy cow and the activity of methanogens in the rumen, DHI data of an integrated gradient boosting tree model is used for analyzing the amino acid balance and precise nutrition technology of the lactating dairy cow, a dairy cow manure yield prediction model based on a Bayesian network is constructed, a manure management strategy is dynamically optimized, and manure management effect data is output. And constructing a carbon emission reduction comprehensive evaluation model, and evaluating the pasture carbon emission reduction effect. According to the invention, the rumen flora structure is regulated and controlled, the rumen greenhouse gas emission is controlled, the ruminant feed protein level is reduced, and the methane emission is reduced by researching the dairy cow carbon emission rumen microorganism regulation and control technology.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The present invention relates to the treatment of cancer, including colorectal cancer (CRC), by inhibiting or blocking Annexin 1. The present invention also relates to the prevention of CRC in high risk patients by inhibiting or blocking Annexin A1. The present invention also relates to the reduction of chemotherapy resistance by inhibiting or blocking Annexin A1. The present invention also relates to the detection of poor prognosis in subjects with CRC by detecting or measuring the expression level of ANXA1 and / or the protein level of Annexin 1.

The invention belongs to the technical field of biological medicine, and particularly provides application of flufenidone in preparation of a medicine for preventing or treating left heart failure. The research finds that the flufenidone has the effects of relieving myocardial cell hypertrophy under a heart failure cell model and relieving myocardial hypertrophy, fibrosis and heart function deterioration of an aortic constriction animal model. According to the present invention, further research results show that fluorofenidone is directly combined with SERCA2a through Q758, D812 and E917 residues of SERCA2a so as to inhibit recognition, combination and polyubiquitination effects of WWP1 on SERCA2a, such that the protein level and the activity of SERCA2a are stabilized so as to achieve the chronic left heart failure treatment purpose. Therefore, the flufenidone serving as an active ingredient has good application prospect and application value in research and development of novel medicines for treating chronic left heart failure.

The application relates to a compound medicine for delaying skeletal muscle aging and application thereof, and the medicinal active components in the compound medicine composition are composed of menadione bisulfite sodium and N-acetyl cysteine, and belong to the technical field of biological medicine. A novel drug combination mode is developed, an oxidant menadione bisulfite sodium (MBS) and an antioxidant N-acetyl-L-cysteine (NAC) are combined and given in different time periods to regulate the H2O2 circadian rhythm of the skeletal muscle of old mice, the changes of the muscle strength, histopathology and aging marker protein level of the skeletal muscle of the old mice are detected, and then the precise compound medicine capable of improving the skeletal muscle function of the old mice and delaying skeletal muscle aging is determined. The application provides an effective drug combination strategy for relieving or treating the delay of skeletal muscle aging, and has very significant meaning.

The application provides an arginine methyltransferase 6 inhibitor and a preparation method, a pharmaceutical composition and a use thereof, relates to the technical field of biological medicine. The arginine methyltransferase 6 inhibitor provided by the application is a new compound obtained on the basis of a large number of design, synthesis and screening. The arginine methyltransferase 6 inhibitor is different from existing PRMTs inhibitors. The arginine methyltransferase 6 inhibitor can selectively degrade arginine methyltransferase 6, thereby regulating the protein level of arginine methyltransferase 6, has antitumor cell activity, can be used for preventing or treating diseases related to abnormal expression of PRMT6, and provides a new choice for development and application of antitumor drugs. The preparation method of the arginine methyltransferase 6 inhibitor provided by the application adopts raw materials which are easy to obtain, has the advantages of simple synthesis method, safety, easy realization and high yield, and can be used for industrial production.

Provided herein are compounds and compositions thereof that reduce FAK protein levels. In some embodiments, the compounds have structures of Formula I:In some embodiments, the compounds and compositions are provided for treatment of FAK associated diseases such as cancer.

The invention discloses a 2-aminoquinazoline derivative as well as a preparation method and application thereof, and relates to the technical field of organic synthesis. The 2-aminoquinazoline derivative disclosed by the invention has a structure as shown in a formula I or a formula II. On the basis of a simple and efficient synthesis route, a plurality of 2-aminoquinazoline derivatives are rapidly constructed by using commercially available and low-cost raw materials and reagents through modular design; the 2-aminoquinazoline derivative has an obvious protective effect on cytopathy caused by viruses, shows down-regulation effect on virus RNA and protein level, lays a solid foundation for subsequent drug development and optimization, and has a wide application prospect.

The application relates to the field of biological medicine, and provides application of ADRM1 gene / protein in preparation of a drug for treating osteosarcoma. The ADRM1 gene / protein is applied to preparation of the drug for treating osteosarcoma, can significantly inhibit proliferation, migration and invasion ability of tumor cells, and thus delays occurrence and development of the osteosarcoma. By shRNA intervention technology, the expression of ADRM1 is knocked down, the mRNA and protein levels of ADRM1 in 143b and U2OS osteosarcoma cell lines are significantly reduced, short-term proliferation activity and long-term clone formation ability are inhibited, and migration and invasion characteristics of the cells are effectively weakened. After 143b osteosarcoma cells with the knocked-down ADRM1 are inoculated into nude mice, the growth of the tumor formed by the cells is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor is down-regulated, indicating that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of the osteosarcoma.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

The invention relates to the technical field of biological medicines, and particularly discloses application of Creld2 as an early biomarker in diagnosis, prediction or prognosis of sepsis. By detecting the Creld2 protein level of the blood of a patient, early rapid diagnosis of sepsis is realized, or by detecting the Creld2 protein level of the blood of a sepsis patient, severity and 28-day survival condition of sepsis are evaluated. Compared with the prior art, the marker has the advantages that ROC curves for diagnosing sepsis and distinguishing severity of the sepsis are greater than 0.9, so that the Creld2 serving as the early marker of the sepsis has relatively high diagnosis efficiency and has the advantages of high sensitivity and high specificity.

The invention discloses an anti-DLL3 antibody as well as a preparation method, a drug conjugate and application thereof. The anti-DLL3 antibody disclosed by the invention has very good internalization activity, relatively good binding activity with human DLL3 protein and relatively strong affinity at the protein level; the DLL3-targeting antibody coupling drug has good druggability, biological activity and in-vivo and in-vitro anti-tumor activity, and application of cytotoxic drugs in treatment of tumor patients with neuroendocrine characteristics including SCLC can be realized by the DLL3-targeting antibody coupling drug.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

The invention belongs to the technical field of medicines, and discloses application of Dcdc2b in preparation of a medicine for preventing or treating amyotrophic lateral sclerosis. Compared with a control cell pCI, the transcriptional level and the protein level of the Dcdc2b are remarkably reduced in a TDP43M337V cell. The Dcdc2b with low expression in the TDP43M337V cells can reduce the survival of the cells, so that the number of synapses of the cells is reduced, and the Dcdc2b is prompted to reduce the survival of the TDP43M337V cells by reducing the number of synapses.

The application belongs to the technical field of biology and particularly relates to application and a kit of CoL10A1. CoL10A1 is highly expressed in BC tissues and lowly expressed in normal tissues, CoL10A1 is highly expressed at mRNA and protein levels in BCBM tissues, therefore, application of a reagent for detecting CoL10A1 expression in preparation of a breast cancer brain metastasis diagnosis product is proposed, and the diagnosis product can also be used for diagnosing breast cancer.

The invention relates to the technical field of medicine, in particular to a brazilin-containing pharmaceutical composition and a preparation method and application thereof, and preparation raw materials comprise brazilin and a zinc preparation. Through the synergistic effect of the brazilin and the zinc preparation, the fibrosis area after myocardial infarction can be remarkably reduced, the cardiac function after myocardial infarction can be improved, and the cardiac fibrosis degree can be effectively relieved by inhibiting the expression of fibrosis-related genes and proteins at transcription and protein levels.

The application discloses application of an inhibitor targeting NLRP3 gene in promoting axon regeneration after sciatic nerve injury. It is found for the first time that NLRP3 expression in DRG is significantly up-regulated after sciatic nerve injury. Further, by interfering with the expression of NLRP3 through siRNA targeting NLRP3, the protein level of NLRP3 can be significantly inhibited, and the increase of the number of DRG neuron axons, the total length of axons and the longest axon length can be obviously promoted. The in-vitro and in-vivo experimental results show that NLRP3 is a negative regulation factor of axon regeneration after sciatic nerve injury, and targeted inhibition of NLRP3 expression can effectively promote axon regeneration. Based on this, the application provides an siRNA sequence targeting NLRP3 and application of the siRNA sequence in preparation of a drug for promoting axon regeneration after sciatic nerve injury. The application provides a new molecular target and intervention strategy for peripheral nerve injury repair, and has important theoretical research value and clinical application prospect.

The invention discloses a novel molecular chaperone-mediated autophagy (CMA) activating agent, relates to the technical field of biological cells, and is characterized in that the novel molecular chaperone-mediated autophagy activating agent is a novel anti-tumor drug chidamide, and the novel molecular chaperone-mediated autophagy activating agent is a novel anti-tumor drug chidamide. The chidamide can obviously up-regulate the mRNA and protein level of the key protein LAMP2A in the CMA process. According to the present invention, by constructing a human THP1-LAMP2luciferase reporter gene system, the compound capable of activating the LAMP2 promoter is screened from the bulk drug; through cell level primary screening, secondary screening and animal level verification, an effective CMA activator chidamide is finally determined. A good tool is provided for basic research of CMA, and novel drugs are further researched and developed by taking CMA as a target spot.

The invention provides an oligopeptide targeting SUV39H1 and application of the oligopeptide in tumor treatment. The amino acid sequence of the oligopeptide is shown as SEQ ID NO: 1. According to the oligopeptide, a PRMT1 and SUV39H1 binding region is precisely targeted, so that the interaction between the PRMT1 and the SUV39H1 is effectively blocked, meanwhile, the methylation level and the protein level of the SUV39H1 are reduced, and precise targeted intervention on the SUV39H1 is realized. The invention provides a novel SUV39H1 intervention means which is accurate in targeting, high in safety and wide in application range, and the technical bottleneck of current tumor treatment is broken through.

The invention provides an oligopeptide, and a lentiviral expression vector and a recombinant cell for expressing the oligopeptide. The invention further provides application of the compound in tumor treatment. After the oligopeptide is delivered to HT1080 cells through a lentivirus system, the intracellular SLC7A11 protein level is reduced, the intracellular Fe < 2 + > and lipid peroxidation level is remarkably increased, and the oligopeptide has a remarkable inhibition effect on cell proliferation and has the tumor treatment potential.